Stocks Industrials HBIO
NASDAQ · IndustrialsHarvard Bioscience Inc (HBIO)
Harvard Bioscience Inc brought in $87.8M of revenue over the twelve months to June 30, 2026, down 1.1% from a year earlier. It posted a net loss of $10.4M. Operating cash flow minus capital spending left $5.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $6.5M in cash against $36.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Watch HBIO in 60 secondsWhat Harvard Bioscience Inc does
Harvard Bioscience Inc is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker HBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $86.6M | -$56.7M | -$1.28 | $5.5M |
| 2024 | $94.1M | -$12.4M | -$0.28 | -$1.2M |
| 2023 | $112.3M | -$3.4M | -$0.08 | $12.2M |
| 2022 | $113.3M | -$9.5M | -$0.23 | -$438K |
| 2021 | $118.9M | -$288K | -$0.01 | $67K |
| 2020 | $102.1M | -$7.8M | -$0.20 | $8.2M |
Full financial statements: income, balance sheet and cash flow
Where HBIO ranks in Industrials
Latest SEC filings
What Harvard Bioscience Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $22.7M versus the same quarter last year; diluted EPS -$0.64 versus -$0.52.
- August 11, 2026
- August 11, 2026
- June 10, 2026
- June 2, 2026
- May 27, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 4.7% to $20.8M versus the same quarter last year; diluted EPS -$0.77 versus -$11.42.
- May 12, 2026
What is HBIO worth? A DCF from its reported cash flow
Insider trades
What the people running Harvard Bioscience Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 9, 2026 | Eade Katherine A.Director | Received as pay | 16,556 | - |
| June 9, 2026 | Benson Seth BenjaminDirector | Received as pay | 16,556 | - |
| June 9, 2026 | Gagnon Robert E.Director | Received as pay | 16,556 | - |
| June 9, 2026 | Denelsky Stephen JDirector | Received as pay | 16,556 | - |
| June 9, 2026 | Snider WilliamDirector | Received as pay | 16,556 | - |
Who owns HBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| William Snider13D, may seek influence with 3 related filers | 15.97% | March 23, 2026 |
| Weber Capital Management, LLC13G, passive | 7.26% | May 8, 2025 |
| Leviticus Partners LP13G, passive | 5.2% | September 22, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 199,893 shares in total, about $1.6M at the last price.
| Holder | Shares |
|---|---|
| Eade Katherine A.Director | 58,669 |
| Snider WilliamDirector | 48,556 |
| Denelsky Stephen JDirector | 37,556 |
| Gagnon Robert E.Director | 27,556 |
| Benson Seth BenjaminDirector | 27,556 |
Questions about HBIO
What does Harvard Bioscience Inc do?
Harvard Bioscience Inc is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker HBIO.
Is Harvard Bioscience Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.4M on revenue of $87.8M.
How much revenue does Harvard Bioscience Inc make?
Over the twelve months to June 30, 2026 Harvard Bioscience Inc reported revenue of $87.8M. That is 1.1% less than a year earlier.
When did Harvard Bioscience Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from September 22, 2026.
Similar companies
Compare HBIO with
Follow HBIO
Get an email when Harvard Bioscience Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow HBIO: get an email when it filesWhere the numbers come from
Financial figures are the values Harvard Bioscience Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.